Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi

Trial Profile

Open-label Study of Isavuconazole in the Treatment of Participants With Aspergillosis and Renal Impairment or of Participants With Invasive Fungal Disease Caused by Rare Moulds, Yeasts or Dimorphic Fungi

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Isavuconazonium (Primary) ; Isavuconazonium (Primary)
  • Indications Aspergillosis; Blastomycosis; Coccidioidomycosis; Cryptococcosis; Histoplasmosis; Invasive bronchopulmonary aspergillosis; Mycoses; Paracoccidioidomycosis
  • Focus Registrational; Therapeutic Use
  • Acronyms VICAL; VITAL
  • Sponsors Astellas Pharma; Basilea Pharmaceutica
  • Most Recent Events

    • 23 Jun 2019 Trial has been completed in UK, according to European Clinical Trials Database record.
    • 02 May 2019 According to an AVIR Pharma Inc media release, Health Canada's approval of Cresemba was based on data from two Phase 3 clinical trials in adult patients with invasive fungal infections - SECURE and VITAL trials.
    • 29 Oct 2018 Results of pooled analysis evaluating the relationship of isavuconazole and voriconazole minimum inhibitory concentrations (MICs) of Aspergillus pathogens at baseline with all-cause mortality and clinical outcomes following treatment with either drug in the SECURE and VITAL trials published in the Antimicrobial Agents and Chemotherapy
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top